NCT01297400

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Skingenix, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Detailed description

This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.

Conditions

• Burns

Interventions

Type	Name	Description
DRUG	Investigational Drug, MW-III	Topical application, twice a day
DRUG	Silvadene® Cream 1% [Silver Sulfadiazine]	Topical application, twice a day

Timeline

• Start date: 2022-03-11
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2011-02-16
• Last updated: 2026-03-16

Locations

6 sites across 2 countries: United States, Mexico

Regulatory

• FDA-regulated drug study